Molecularly driven therapy recommended by a molecular tumor board: Accessible option or privilege for a minority of patients? A single-center experience from the Czech Republic
| Authors | |
|---|---|
| Year of publication | 2023 |
| Type | Conference abstract |
| Citation |
| Authors | |
|---|---|
| Year of publication | 2023 |
| Type | Conference abstract |
| Citation |